Shots: Shionogi to acquire Tetra for a total value of up to $500M which includes regulatory and commercial milestones, based on certain achievements. Following the acquisition, Shionogi will get global rights to Tetra’s portfolio for CNS disorders including BPN14770 In 2018, the two companies collaborated and in 2020 expand their alliance to develop and commercialize […]Read More
